Cita APA (7a ed.)
Xu, C., Qu, S., Liu, Z., Yang, K., Huang, Y., Guo, L., . . . Ma, J. (2026 Supplement 19). An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial. Journal of Clinical Oncology, 44, 227-247.
Cita Chicago Style (17a ed.)
Xu, Cheng, et al. "An Oral Anlotinib-capecitabine Regimen Plus Penpulimab as First-line Therapy for Recurrent/metastatic Nasopharyngeal Carcinoma (R/M NPC): A Multicenter, Single-arm, Phase 2 Clinical Trial." Journal of Clinical Oncology 44 (2026 Supplement 19): 227-247.
Cita MLA (9a ed.)
Xu, Cheng, et al. "An Oral Anlotinib-capecitabine Regimen Plus Penpulimab as First-line Therapy for Recurrent/metastatic Nasopharyngeal Carcinoma (R/M NPC): A Multicenter, Single-arm, Phase 2 Clinical Trial." Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 227-247.
Precaución: Estas citas no son 100% exactas.